Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Personalis ( (PSNL) ) has issued an update.
Personalis has announced that its NeXT Personal® test, designed for post-treatment surveillance of cancer recurrence, has received Medicare coverage for patients with stage II and III breast cancer. The coverage, effective retroactively from October 7, 2025, includes reimbursement rates for the NeXT Personal Dx Breast MRD Recurrence Monitoring Test and the NeXT Personal Single Plasma Test, potentially enhancing the company’s market position in cancer diagnostics.
The most recent analyst rating on (PSNL) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Personalis stock, see the PSNL Stock Forecast page.
Spark’s Take on PSNL Stock
According to Spark, TipRanks’ AI Analyst, PSNL is a Neutral.
Personalis is facing significant financial and valuation challenges, with declining revenue and profitability issues being the most impactful factors. Technical analysis indicates a bearish trend, though there is potential for a reversal. The earnings call provided some positive insights into clinical adoption and strategic partnerships, but these are overshadowed by financial headwinds.
To see Spark’s full report on PSNL stock, click here.
More about Personalis
Average Trading Volume: 1,071,891
Technical Sentiment Signal: Buy
Current Market Cap: $615.4M
For a thorough assessment of PSNL stock, go to TipRanks’ Stock Analysis page.